Lung Cancer News and Research

Latest Lung Cancer News and Research

Study identifies cellular adhesion molecules key to cancer metastasis

Although tumor metastasis causes about 90 percent of cancer deaths, the exact mechanism that allows cancer cells to spread from one part of the body to another is not well understood. One key question is how tumor cells detach from the structural elements that normally hold tissues in place, then reattach themselves in a new site.

10 Oct 2012

Data from GTx's enobosarm Phase IIb study on cancer to be presented at SIOG meeting

GTx, Inc. announced today there will be two scientific poster presentations on the effects of enobosarm, a selective androgen receptor modulator (SARM), on improving physical function and quality of life in middle aged and elderly cancer patients.

8 Oct 2012

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute and published in the October issue of Anticancer Research.

8 Oct 2012

NFKB1 gene variant may reduce risk of lung cancer

A variant in a gene involved with inflammation and the immune response is linked with a decreased risk of lung cancer. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The results add to the growing body of literature implicating these processes in the development of lung cancer.

8 Oct 2012

DPP-inhibitors reduce cardiovascular events in diabetes patients

Type 2 diabetes patients who are treated with dipeptidyl peptidase-4 inhibitors have a significantly reduced risk for cardiovascular events, particularly myocardial infarction, compared with their peers who take placebo or other drugs, results of a meta-analysis show.

5 Oct 2012

Urgent action needed to improve outcomes for lung cancer patients, says expert

Urgent action is needed to improve outcomes for lung cancer patients, a leading lung cancer expert will explain in a public lecture at the University of Leicester.

5 Oct 2012

IDIBELL, Universitat Politècnica de Catalunya patent novel system to improve lung cancer diagnosis

The system guides physicians by describing the best bronchoscope route from the trachea to a peripheral lung lesion. It avoids futile examinations and minimises potential risk for the patient.

5 Oct 2012

New book on natural interventions for lung cancer

Told he had lung cancer and 6 months to live, the author refused chemo/surgery and used holistic, natural, non-invasive interventions. Now, 38 years later at age 80 he not only beat the odds of lung cancer but also the odds of 3 chronic illnesses and 5 prescribed medications that are the average for a 75 year old.

5 Oct 2012

CINJ physicians named among 2012 list of U.S. News Top Doctors

Several physicians at The Cancer Institute of New Jersey (CINJ), who are faculty members at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, have been named as a 'Top Doctor' by U.S. News & World Report.

5 Oct 2012

Chronic kidney disease independently increases mortality risk

Findings from two meta-analyses published in The Lancet show that patients with chronic kidney disease are at high risk for death and end-stage renal disease even if they do not have comorbid hypertension or diabetes.

4 Oct 2012

Vulnerability to ‘thin ideal’ may be genetic

Results from a study carried out in identical and nonidentical twins suggests that a woman’s risk for thin-ideal internalization may be genetic.

4 Oct 2012

Routine screening influences outcomes in prostate cancer after surgery

Men who undergo radical prostatectomy for a tumor that was detected by screening show better long-term outcomes than their peers who undergo the surgery after opportunistic diagnosis, study results show.

3 Oct 2012

BMI concerns raised for childhood stem cell transplantation survivors

Childhood survivors of hematologic malignancies treated with allogeneic hematopoietic stem cell transplantation should undergo long-term monitoring of their body mass index and lean body mass, US researchers recommend.

3 Oct 2012

Synthetic hybrid molecules more effectively tackle chemo-resistant cancers

When Linda Tuttle was diagnosed with breast cancer, she never imagined her experience would inspire her colleagues to design new treatments to tackle the disease.

3 Oct 2012

Statins linked to reduced glaucoma risk

Cholesterol-lowering medications in the statin class could significantly reduce the risk for developing open-angle glaucoma, show data for more than 500,000 older-age US individuals with hyperlipidemia.

2 Oct 2012

Hormone and androgen receptor genes combined affect sperm motility

The combination of alleles for genes encoding the follicle-stimulating hormone receptor and androgen receptor has a significant impact on sperm motility, emphasising the importance of the genes in sperm quality, say Greek scientists.

1 Oct 2012

WBC counts in diabetes risk prediction

An elevated white blood cell count in young men is an independent predictor for the development of diabetes in later life, suggest study findings.

1 Oct 2012

Cholesterol has repercussions for recovering heroin addicts

Cholesterol levels may be negatively associated with heroin craving in patients on methadone maintenance therapy, researchers suggest.

1 Oct 2012

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).

1 Oct 2012

Crizotinib effectively treats patients with ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012